The ZOE COVID Study’s positive symptomatic case estimate is currently 108,951 cases (+7.8% in a week). The 7-day estimate shows 728,348 cases (-2.3%). On average, it is now estimated that at least 104,050 people are still infected by coronavirus every day in the UK.
Vaccination remains the best defence against severe disease and hospitalisation. It is also sensible to wear a face covering in crowded, enclosed spaces.
First published in September 2022.
- 📆 Latest Summary
- ⏰ Latest Guidance
- 📻 Latest News
- 🐦 Tweets
- 📌 Must-Read
- 🧬 Variants News
- 💉 Vaccination Data
- 🧩 Long COVID
- 📄 Additional Data
- 📚 Data Sources
Latest UK Dashboard
Our reporting strategy
Since 27 July we don’t publish the UKHSA data in our daily reporting. Those figures are just conveniently and undoubtedly flawed. Instead, we now focus on the ZOE COVID Study and the ONS Infection Survey data.
Our readers deserve the truth about COVID-19 and the UK government has clearly been doing everything – from ending free tests to irregular dashboard reports, delaying and ending some data reports – to make sure the media slowly lose interest in COVID reporting and get the public to believe both that they can live with the virus and that the pandemic is over. This is wrong and untrue, as the WHO and most public health experts have repeatedly told us.
For these reasons, PMP Magazine has so far, and will continue to publish COVID daily updates because we see it as part of our mission to always report the truth, even if it means we are the last media in the UK to do so.
While others are sleepwalking to hide the inconvenient truth about COVID-19, PMP Magazine isn’t giving up! Our daily report is free and accessible to all.
Please support our work with a donation: PMP-Magazine.com/crowdfunding
COVID is not over.
Reminder on data reporting in the UK
▫ Since 1 July 2022, the COVID-19 UKHSA Dashboard has moved to weekly reporting. From 8 September 2022, updates take place on Thursdays.
▫ The reporting of ZOE COVID Study data has remained daily.
▫ The reporting of ONS Infection Survey data has remained weekly with a 7-day lag.
(Source: UKHSA | ZOE | ONS)
Zoe COVID Study Estimates
■ Daily Estimated Cases
After having plateaued for a couple of weeks, we seem to have reached an inflection point this week. How prepared are we for the inevitable autumn and winter waves?
ONS Infection Survey Estimates
■ Weekly Estimates Cases
The percentage of people testing positive for coronavirus continued to decrease in England, Wales and Scotland in the latest week (ending 23 August 2022). The trend was uncertain in Northern Ireland.
■ Weekly COVID-19 Recorded Deaths
Deaths involving COVID-19 increased in the UK
According to the ONS, 621 involved COVID-19, down from 675 in the previous week. This meant COVID-19 deaths accounted for 5.0% of all deaths in the latest week, a decrease from 5.7% in the previous week.
In England, the number of deaths involving COVID-19 decreased from 561 in the previous week to 520 in the latest week (ending 19 August 2022). The number of deaths involving COVID-19 in England decreased in groups aged 65 to 84 years, increased slightly in those aged 45 to 55 years, and remained similar for all other age groups.
■ UK Government’s List of symptoms of COVID-19
After two years without updating its list of just three symptoms of COVID-19 (a high temperature, a new continuous cough and a loss or change to the sense of smell or taste), the NHS has finally updated its list of symptoms of COVID:
😩 Shortness of breath
🥱 Feeling tired or exhausted
🤕 An aching body
🤯 A headache
🤐 A sore throat
🤧 A blocked or runny nose
😞 Loss of appetite
🤮 Feeling sick or being sick
■ TRAVEL: ENTRY RULES AND RESTRICTIONS
Check out the latest situation for 20 of the top travel destinations for Brits:
■ ZOE COVID Study’s Top 20 symptoms of COVID-19 (as of 25-Aug-2022)
JCVI advises use of additional bivalent vaccine for autumn booster campaign — UKHSA
Following on from the previous advice on which vaccines should be used in this year’s autumn booster programme, the Joint Committee on Vaccination and Immunisation (JCVI) has updated its published advice to include an additional bivalent vaccine now approved by the Medicines and Healthcare products Regulatory Agency (MHRA).
Studies indicate the Pfizer-BioNTech bivalent vaccine produces a marginally higher immune response against some variants than the Pfizer-BioNTech mRNA Original ‘wild-type’ vaccine. The clinical relevance of these small differences is uncertain
‘Bivalent’ vaccines have been developed by global manufacturers since the emergence and dominance of the Omicron variant. These vaccines are targeted against antigens (substances that induce an immune response) from 2 different COVID-19 strains, or variants.
All of the available booster vaccines offer very good protection against severe illness from COVID-19. As more vaccines continue to be developed, the committee will consider their use in the autumn programme.
Professor Wei Shen Lim, Chair of COVID-19 immunisation on the JCVI, said:
“It is very encouraging that more vaccines continue to become available and we now have another option to add to the vaccines already advised for the autumn booster campaign.
“Winter is typically the time of greatest threat from respiratory infections. We strongly encourage everyone who is eligible to have their booster vaccine this autumn when it is offered. This is our best defence against becoming severely ill from COVID-19.”
sign up to our FREE Briefings today.
we need your help
Since February 2022, the UKHSA has slowly reduced the publishing of its daily COVID updates, following the UK Government’s narrative that we should all “live with the virus”. UKHSA now reports only once a week.
The virus doesn’t take a break 6 days a week.
It doesn’t infect people from time to time.
It doesn’t stop at a border either.
The virus still spreads and kills people every day in the UK and around the world. COVID-19 is NOT over.
We, at PMP, have decided to continue to publish the latest COVID data available every day, especially the Zoe COVID Study estimates – probably more accurate than the UK Government’s own data since free testing has ended in England, and the ONS COVID Infection Survey estimates.
Please, support our work through our crowdfunding to help us to continue our COVID reporting: Donate now.
■ 🧬 COG-UK sequencing
💉 Latest UK Vaccination
Note: UK vaccination data is now published weekly on Wednesdays.
Note: Data cross-referenced with the latest official data from the UK dashboard.
Total UK population: 67,081,234 (last year: 66,796,800), via ONS (subject to changes in population over the year). These figures were updated on 25 June 2021. (Source: ONS)
🚨 2 million people currently live with long COVID in the UK (vs 1.8 million last month)
🚨 3.1% of the UK population currently live with long COVID (vs 2.8%)
🚨 1 in 33 people in the UK has long COVID
🚨 Long COVID symptoms still adversely affect the day-to-day activities of 1.5 million people, 73% of long COVID sufferers (vs 1.3 million)
🚨 Of those, 384,000 people (19%) are “limited a lot” (vs 369,000)
🚨 582,000 (29%) first had COVID-19 before Alpha became the main variant; 256,000 (13%) in the Alpha period, 386,000 (19%) in the Delta period, and 681,000 (34%) in the Omicron period.
🚨 Most common symptoms of long COVID
▫ fatigue (62%) ▲
▫ shortness of breath (37%) ▲
▫ difficulty concentrating (33%) ▲
▫ muscle ache (31%) ▲
🚨 Prevalence of long COVID is greatest in people
▫ aged 35-69 years
▫ living in more deprived areas
▫ working in social care
▫ with another activity limiting health condition or disability
🚨 Long COVID by occupation (ONS – 29 Jun-2022)
▫ Police and protective services (25%)
▫ Education (22%)
▫ Social care sector (22%)
Note: There has been a change in the way the data are collected by the ONS. As a result, these estimates are not fully comparable with those in previous bulletins. For more details on these changes, please see the Impact of moving to remote data collection.
Long COVID News
long covid kids
🧩 Long COVID Kids
According to a recent systematic review and meta-analyses of Long-COVID in children and adolescents published in Nature:
🚨 Long COVID affects 1 in 4 infected children (25.24%)
🚨 For hospitalised children, prevalence of long-COVID is nearly 1 in 3 infected children (29.19%)
🚨 Most prevalent clinical manifestations of Long COVID in children/adolescents:
▫ mood symptoms (16.50%)
▫ fatigue (9.66%)
▫ sleep disorders (8.42%)
▫ headache (7.84%)
▫ respiratory symptoms (7.62%)
▫ sputum production or nasal congestion (7.53%)
▫ cognitive symptoms (6.27%)
▫ loss of appetite (6.07%)
▫ exercise intolerance (5.73%)
▫ altered smell (5.60%)
🚨 Children infected by COVID-19 have a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever
🚨 Like adults, the pediatric population’s risk factors associated with long-COVID are:
▫ older age children
▫ female gender
▫ severe COVID-19
▫ comorbid allergic diseases and other long-term co-morbidities
The authors of the systematic review and meta-analyses of Long-COVID in children and adolescents conclude:
“Long-COVID represents a significant public health concern, and there are no guidelines to address its diagnosis and management.
“Our meta-analyses further support the importance of continuously monitoring the impact of long-COVID in children and adolescents and the need to include all variables and appropriate control cohorts in studies to better understand the real burden of pediatric long-COVID.”
■ Number of contact tracing alerts sent (England & Wales)
(Source: University of Oxford)
📚 Data Sources:
- Daily summary: Coronavirus in the UK | UK Government
- Coronavirus (COVID-19) NHS Advice | PMP Magazine
- Variants: distribution of cases data | UK Health Security Agency (UKHSA)
- Vaccination Data | UK Government
- What’s new | UK Government
— AUTHOR —
- Text: This piece was first published in PMP Magazine on 4 Sept 2022. | The authors write in a personal capacity.
- Data cross-referenced with the latest official data from the UK dashboard.
- Cover: Adobe Stock/SergeyBitos.
- Icons from www.flaticon.com